Dublin, May 01, 2019 (GLOBE NEWSWIRE) -- The "US Breast Cancer Drug Market, Price, Dosage & Clinical Pipeline Insight 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.

Breast cancer is the most commonly diagnosed cancer in American women. Breast cancer occurring in a woman under 40 is not a typical condition anymore. Changing lifestyles with numerous other factors like early menarche, late age at first childbirth, late menopause and prolonged exposure to endogenous oestrogens are surging the breast cancer drug market at a high rate. Also, short breast-feeding timeframes, a rise in obesity in women after menopause, increasing rate of alcohol consumption in women, rising use of hormone replacement therapy (HRT) and oral birth control pills which causes increased levels of oestrogen are boosting the breast cancer drug market to its peak.

Various breast cancer therapeutics have come into existence like hormone drugs, chemotherapy drugs and targeted drugs. With advancements in drug delivery systems, target-specific therapies are prevailing. Also, ER-positive drugs for breast cancer are being introduced to the market. Drugs approved for the prevention of breast cancer like Raloxifene Hydrochloride, Elvista, etc. and drugs approved for the treatment of breast cancer like Abemaciclib, Abraxane, Xeloda, Taxol, Methotrexate, etc. have been mentioned in detail with indication, dosing and pricing in this report on US Breast Cancer Drug Market.

Key highlights of this report:

• US Breast Cancer Drug Market Opportunity: US$ 20 Billion
• US Breast Cancer Drug Clinical Pipeline by Company, Phase, Drug Class & Patient Segment
• US Breast Cancer Marketed Drugs: 42 Drugs
• US Breast Cancer Drug Clinical Pipeline: 317 Drugs
• Dosage & Pricing Insight for Preventive & Treatment Drugs
• US Breast Cancer Drug Market Dynamics

Key Topics Covered:

1. US - Cancer Incidence & Prevalence

2. US Breast Cancer Market Landscape
2.1 Incidence & Prevalence
2.2 Diagnosis of Breast Cancer

3. US Breast Cancer Drug Market
3.1 Overview US Breast Cancer Drug Market
3.2 Diagnosis & Screening Market Scenario
3.3 US Breast Cancer Clinical Pipeline Overview (Phase, Drug Class, Company, Patient Segment)

4. Forward-Looking Developments in Breast Cancer Drug Market
4.1 ER Positive Breast Cancer
4.1.1 CDK4/6 Inhibitors
4.1.2 PI3K Inhibitors
4.1.3 Crizotinib for Lobular Breast Cancer
4.2 HER2-Positive Breast Cancer
4.2.1 Palbociclib & Herceptin (Spain)
4.2.2 Tecentriq - FDA Approval for Breast Cancer
4.3 Triple Negative Breast Cancer
4.3.1 Atezolizumab & Nab-Paclitaxel
4.3.2 Sacituzumab Govitecan
4.3.3 Carboplatin & Docetaxel

5. US - Dosage & Pricing Insight for Drugs Approved for the Prevention of Breast Cancer
5.1 Raloxifene Hydrochloride
5.2 Elvista
5.3 Tamoxifen Citrate

6. US - Dosage & Pricing Insight for Drugs Approved for the Treatment of Breast Cancer
6.1 Abemaciclib
6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
6.3 Ado-Trastuzumab Emtansine
6.4 Afinitor (Everolimus)
6.5 Anastrozole
6.6 Aromasin (Exemestane)
6.7 Xeloda (Capecitabine)
6.8 Docetaxel (Docetaxel Anhydrous)
6.9 Doxorubicin Hydrochloride
6.10 Ellence (Epirubicin Hydrochloride)
6.11 Fluorouracil
6.12 Taxol (Paclitaxel)
6.13 Methotrexate
6.14 Cyclophosphamide

7. US Breast Cancer Drug Market Dynamics
7.1 Market Drivers
7.1.1 Increasing Incidence of Breast Cancer
7.1.2 Research & Development for Novel Drugs
7.1.3 Increase in Healthcare Expenditure & Funding
7.1.4 Increasing Breast Cancer Screening Programs
7.1.5 Rising Consumption of Tobacco & Alcohol
7.2 US Breast Cancer Drug Market Challenges
7.2.1 Pricing Pressure Experienced by the Innovators
7.2.2 High Cost associated with Drug Development & Clinical Trials
7.2.3 Obstacles to the Incorporation of New Therapies for Breast Cancer

8. US - Breast Cancer Drug Market Forecast
8.1 Future Potential of US Breast Cancer Drug Market
8.2 Opportunities for Forthcoming Drug Classes

9. US - Breast Cancer Drug Clinical Pipeline by Company & Phase
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-II/III
9.8 Phase-III
9.9 Preregistration
9.10 Registered

10. US - Marketed Breast Cancer Drug Clinical Insight by Company
10.1 Afinitor
10.2 LYNPARZA
10.3 Abraxane
10.4 Verzenio
10.5 Kisqali
10.6 Lymphoseek
10.7 Kadcyla
10.8 Ibrance
10.9 Nerlynx
10.10 Soltamox
10.11 Tykerb
10.12 Zoladex
10.13 Omnitarg, Perjeta
10.14 Halaven
10.15 Taxotere
10.16 Other( 27 Drugs Profiles)

11. Competitive Landscape
11.1 Agilent Technologies
11.2 AstraZeneca
11.3 Bayer HealthCare Pharmaceuticals
11.4 Bristol-Myers Squibb
11.5 Eisai Co Ltd
11.6 Eli Lilly
11.7 Novartis
11.8 Onyx Pharmaceuticals
11.9 Orion
11.10 Perrigo
11.11 Pfizer
11.12 Roche

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/wx6igu

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Women's Health, Breast Cancer Drugs